Table 3.
Post‐transfusion major cross‐match test results (DEA 1‐matched blood; 2nd follow‐up period) between plasma samples from 8 recipients and RBCs from 34 dogs (representing 4 different RBC panels based on DEA 1 and DEA 7 typing)
| Panel blood type | n | Number of incompatible cross‐match results with each recipient | |||||||
|---|---|---|---|---|---|---|---|---|---|
| R1 | R6 | R7 | R10 | R13 | R14 | R17 | R22 | ||
|
Panel 1 DEA 1−, 7− |
11 | 0 | 10 | 1 | 0 | 11 | 6 | 0 | 11 |
|
Panel 2 DEA 1−, 7+ |
4 | 0 | 4 | 1 | 0 | 4 | 2 | 0 | 4 |
|
Panel 3 DEA 1+, 7− |
11 | 0 | 9 | 0 | 9 | 11 | 9 | 1 | 9 |
|
Panel 4 DEA 1+, 7+ |
8 | 0 | 6 | 2 | 5 | 8 | 7 | 1 | 8 |
| All panels | 34 | 0 | 29 | 4 | 14 | 34 | 24 | 2 | 32 |
| Overall incompatibility | % | 0 | 85 | 12 | 41 | 100 | 71 | 6 | 94 |
DEA, Dog erythrocyte antigen, R, dog recipient number; n, number of dogs in each panel.
R1: negative control, DEA 1−, 7+; R6: DEA 1−, DEA 7 blood type was not determined; R7: DEA 1−, 7−; R10 & R13: DEA 1+, 7−; R14 & R17: DEA 1+, 7+; R22: DEA 1+, DEA 7 blood type was not determined.
Of the 34 healthy dogs (27 donors, 7 control dogs), 11 dogs were DEA 1− and DEA 7− (Panel 1), 4 were DEA 1− and DEA 7+ (Panel 2), 11 were DEA 1+ and DEA 7− (Panel 3) and 8 were DEA 1+, and DEA 7+ (Panel 4).